Nuvonis Receives Grant to Expand Cell Line Platform

Nuvonis is proud to announce that we have been awarded a grant from the Vienna Business Agency. A service offered by the City of Vienna to establish a new avian suspension cell line for vaccine manufacturing.

This funding will enable us to expand our cell line platform beyond our current Vero and proprietary quail cell lines (CCX.E10 and CCX.2C4). By developing a new avian suspension cell line, we will offer even more options for efficient vaccine production, leveraging our expertise in virus production.

Our goal is to provide the pharmaceutical industry with a wider range of high-quality, fully characterized GMP cell lines to accelerate vaccine/vector development and production.

Stay tuned for updates on our progress as we work towards expanding our cell line portfolio.